What is the projected market valuation for the NTRK Fusion Gene Positive Advanced Solid Tumor Market in 2035?

The projected market valuation for 2035 is 83.61 USD Billion. Read More

What was the overall market valuation for this segment in 2024?

The overall market valuation was 13.51 USD Billion in 2024. Read More

What is the expected CAGR for the NTRK Fusion Gene Positive Advanced Solid Tumor Market from 2025 to 2035?

The expected CAGR during the forecast period 2025 - 2035 is 18.02%. Read More

Which treatment type is projected to have the highest valuation by 2035?

Surgery is projected to reach a valuation of 20.0 USD Billion by 2035. Read More

How does the market size for advanced stage tumors compare to metastatic stage tumors in 2035?

By 2035, advanced stage tumors are projected to reach 32.8 USD Billion, while metastatic stage tumors are expected to reach 34.31 USD Billion. Read More

What are the projected valuations for NTRK gene fusion positive biomarkers by 2035?

NTRK1, NTRK2, and NTRK3 gene fusion positive biomarkers are projected to reach 21.0, 25.0, and 37.6 USD Billion respectively by 2035. Read More

What is the projected market size for breast cancer treatment in 2035?

The projected market size for breast cancer treatment is 20.0 USD Billion by 2035. Read More

How does the market for chemotherapy compare to targeted therapy in 2035?

By 2035, chemotherapy is projected to reach 15.0 USD Billion, whereas targeted therapy is expected to reach 18.0 USD Billion. Read More

What is the expected market size for colorectal cancer treatment by 2035?

The expected market size for colorectal cancer treatment is projected to be 15.0 USD Billion by 2035. Read More

Ntrk Fusion Gene Positive Advanced Solid Tumor Market

Q: Which key players are leading the NTRK Fusion Gene Positive Advanced Solid Tumor Market?

Key players include Bayer, Bristol Myers Squibb, Eli Lilly and Company, Genentech, Merck & Co., Novartis, Pfizer, Roche, and Blueprint Medicines. Read More

ID: MRFR/LS/25961-HCR

100 Pages

Rahul Gotadki

Last Updated: April 06, 2026

NTRK Fusion Gene Positive Advanced Solid Tumor Market Research Report By Treatment Type (Targeted Therapy, Chemotherapy, Immunotherapy, Surgery, Radiation Therapy), By Tumor Type (Lung Cancer, Colorectal Cancer, Breast Cancer, Pancreatic Cancer, Sarcoma), By Market Stage (Early Stage, Advanced Stage, Metastatic Stage), By Biomarker Status (NTRK1 Gene Fusion Positive, NTRK2 Gene Fusion Positive, NTRK3 Gene Fusion Positive) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Ntrk Fusion Gene Positive Advanced Solid Tumor Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)18.02%

2024 Market Size$ 13.51 Billion

2025 Market Size$ 15.95 Billion

2035 Market Size$ 83.61 Billion

Key Players

Bayer

Bristol Myers Squibb

Eli Lilly and Company

Genentech

Merck & Co.

Novartis

Trends

Rise of Targeted Therapies
Increased Genetic Testing
Collaboration Between Stakeholders

Opportunities

Rising Incidence of Solid Tumors
Advancements in Precision Medicine
Growing Awareness of Genetic Testing

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Treatment Type (USD Billion)
  1. 4.1.1 Targeted Therapy
  2. 4.1.2 Chemotherapy
  3. 4.1.3 Immunotherapy
  4. 4.1.4 Surgery
  5. 4.1.5 Radiation Therapy
2. 4.2 Healthcare, BY Tumor Type (USD Billion)
  1. 4.2.1 Lung Cancer
  2. 4.2.2 Colorectal Cancer
  3. 4.2.3 Breast Cancer
  4. 4.2.4 Pancreatic Cancer
  5. 4.2.5 Sarcoma
3. 4.3 Healthcare, BY Market Stage (USD Billion)
  1. 4.3.1 Early Stage
  2. 4.3.2 Advanced Stage
  3. 4.3.3 Metastatic Stage
4. 4.4 Healthcare, BY Biomarker Status (USD Billion)
  1. 4.4.1 NTRK1 Gene Fusion Positive
  2. 4.4.2 NTRK2 Gene Fusion Positive
  3. 4.4.3 NTRK3 Gene Fusion Positive
5. 4.5 Healthcare, BY Region (USD Billion)
  1. 4.5.1 North America
    1. 4.5.1.1 US
    2. 4.5.1.2 Canada
  2. 4.5.2 Europe
    1. 4.5.2.1 Germany
    2. 4.5.2.2 UK
    3. 4.5.2.3 France
    4. 4.5.2.4 Russia
    5. 4.5.2.5 Italy
    6. 4.5.2.6 Spain
    7. 4.5.2.7 Rest of Europe
  3. 4.5.3 APAC
    1. 4.5.3.1 China
    2. 4.5.3.2 India
    3. 4.5.3.3 Japan
    4. 4.5.3.4 South Korea
    5. 4.5.3.5 Malaysia
    6. 4.5.3.6 Thailand
    7. 4.5.3.7 Indonesia
    8. 4.5.3.8 Rest of APAC
  4. 4.5.4 South America
    1. 4.5.4.1 Brazil
    2. 4.5.4.2 Mexico
    3. 4.5.4.3 Argentina
    4. 4.5.4.4 Rest of South America
  5. 4.5.5 MEA
    1. 4.5.5.1 GCC Countries
    2. 4.5.5.2 South Africa
    3. 4.5.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Bayer (DE)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Bristol Myers Squibb (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Eli Lilly and Company (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Genentech (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Merck & Co. (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Novartis (CH)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Pfizer (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Roche (CH)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Blueprint Medicines (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY TREATMENT TYPE
4. 6.4 US MARKET ANALYSIS BY TUMOR TYPE
5. 6.5 US MARKET ANALYSIS BY MARKET STAGE
6. 6.6 US MARKET ANALYSIS BY BIOMARKER STATUS
7. 6.7 CANADA MARKET ANALYSIS BY TREATMENT TYPE
8. 6.8 CANADA MARKET ANALYSIS BY TUMOR TYPE
9. 6.9 CANADA MARKET ANALYSIS BY MARKET STAGE
10. 6.10 CANADA MARKET ANALYSIS BY BIOMARKER STATUS
11. 6.11 EUROPE MARKET ANALYSIS
12. 6.12 GERMANY MARKET ANALYSIS BY TREATMENT TYPE
13. 6.13 GERMANY MARKET ANALYSIS BY TUMOR TYPE
14. 6.14 GERMANY MARKET ANALYSIS BY MARKET STAGE
15. 6.15 GERMANY MARKET ANALYSIS BY BIOMARKER STATUS
16. 6.16 UK MARKET ANALYSIS BY TREATMENT TYPE
17. 6.17 UK MARKET ANALYSIS BY TUMOR TYPE
18. 6.18 UK MARKET ANALYSIS BY MARKET STAGE
19. 6.19 UK MARKET ANALYSIS BY BIOMARKER STATUS
20. 6.20 FRANCE MARKET ANALYSIS BY TREATMENT TYPE
21. 6.21 FRANCE MARKET ANALYSIS BY TUMOR TYPE
22. 6.22 FRANCE MARKET ANALYSIS BY MARKET STAGE
23. 6.23 FRANCE MARKET ANALYSIS BY BIOMARKER STATUS
24. 6.24 RUSSIA MARKET ANALYSIS BY TREATMENT TYPE
25. 6.25 RUSSIA MARKET ANALYSIS BY TUMOR TYPE
26. 6.26 RUSSIA MARKET ANALYSIS BY MARKET STAGE
27. 6.27 RUSSIA MARKET ANALYSIS BY BIOMARKER STATUS
28. 6.28 ITALY MARKET ANALYSIS BY TREATMENT TYPE
29. 6.29 ITALY MARKET ANALYSIS BY TUMOR TYPE
30. 6.30 ITALY MARKET ANALYSIS BY MARKET STAGE
31. 6.31 ITALY MARKET ANALYSIS BY BIOMARKER STATUS
32. 6.32 SPAIN MARKET ANALYSIS BY TREATMENT TYPE
33. 6.33 SPAIN MARKET ANALYSIS BY TUMOR TYPE
34. 6.34 SPAIN MARKET ANALYSIS BY MARKET STAGE
35. 6.35 SPAIN MARKET ANALYSIS BY BIOMARKER STATUS
36. 6.36 REST OF EUROPE MARKET ANALYSIS BY TREATMENT TYPE
37. 6.37 REST OF EUROPE MARKET ANALYSIS BY TUMOR TYPE
38. 6.38 REST OF EUROPE MARKET ANALYSIS BY MARKET STAGE
39. 6.39 REST OF EUROPE MARKET ANALYSIS BY BIOMARKER STATUS
40. 6.40 APAC MARKET ANALYSIS
41. 6.41 CHINA MARKET ANALYSIS BY TREATMENT TYPE
42. 6.42 CHINA MARKET ANALYSIS BY TUMOR TYPE
43. 6.43 CHINA MARKET ANALYSIS BY MARKET STAGE
44. 6.44 CHINA MARKET ANALYSIS BY BIOMARKER STATUS
45. 6.45 INDIA MARKET ANALYSIS BY TREATMENT TYPE
46. 6.46 INDIA MARKET ANALYSIS BY TUMOR TYPE
47. 6.47 INDIA MARKET ANALYSIS BY MARKET STAGE
48. 6.48 INDIA MARKET ANALYSIS BY BIOMARKER STATUS
49. 6.49 JAPAN MARKET ANALYSIS BY TREATMENT TYPE
50. 6.50 JAPAN MARKET ANALYSIS BY TUMOR TYPE
51. 6.51 JAPAN MARKET ANALYSIS BY MARKET STAGE
52. 6.52 JAPAN MARKET ANALYSIS BY BIOMARKER STATUS
53. 6.53 SOUTH KOREA MARKET ANALYSIS BY TREATMENT TYPE
54. 6.54 SOUTH KOREA MARKET ANALYSIS BY TUMOR TYPE
55. 6.55 SOUTH KOREA MARKET ANALYSIS BY MARKET STAGE
56. 6.56 SOUTH KOREA MARKET ANALYSIS BY BIOMARKER STATUS
57. 6.57 MALAYSIA MARKET ANALYSIS BY TREATMENT TYPE
58. 6.58 MALAYSIA MARKET ANALYSIS BY TUMOR TYPE
59. 6.59 MALAYSIA MARKET ANALYSIS BY MARKET STAGE
60. 6.60 MALAYSIA MARKET ANALYSIS BY BIOMARKER STATUS
61. 6.61 THAILAND MARKET ANALYSIS BY TREATMENT TYPE
62. 6.62 THAILAND MARKET ANALYSIS BY TUMOR TYPE
63. 6.63 THAILAND MARKET ANALYSIS BY MARKET STAGE
64. 6.64 THAILAND MARKET ANALYSIS BY BIOMARKER STATUS
65. 6.65 INDONESIA MARKET ANALYSIS BY TREATMENT TYPE
66. 6.66 INDONESIA MARKET ANALYSIS BY TUMOR TYPE
67. 6.67 INDONESIA MARKET ANALYSIS BY MARKET STAGE
68. 6.68 INDONESIA MARKET ANALYSIS BY BIOMARKER STATUS
69. 6.69 REST OF APAC MARKET ANALYSIS BY TREATMENT TYPE
70. 6.70 REST OF APAC MARKET ANALYSIS BY TUMOR TYPE
71. 6.71 REST OF APAC MARKET ANALYSIS BY MARKET STAGE
72. 6.72 REST OF APAC MARKET ANALYSIS BY BIOMARKER STATUS
73. 6.73 SOUTH AMERICA MARKET ANALYSIS
74. 6.74 BRAZIL MARKET ANALYSIS BY TREATMENT TYPE
75. 6.75 BRAZIL MARKET ANALYSIS BY TUMOR TYPE
76. 6.76 BRAZIL MARKET ANALYSIS BY MARKET STAGE
77. 6.77 BRAZIL MARKET ANALYSIS BY BIOMARKER STATUS
78. 6.78 MEXICO MARKET ANALYSIS BY TREATMENT TYPE
79. 6.79 MEXICO MARKET ANALYSIS BY TUMOR TYPE
80. 6.80 MEXICO MARKET ANALYSIS BY MARKET STAGE
81. 6.81 MEXICO MARKET ANALYSIS BY BIOMARKER STATUS
82. 6.82 ARGENTINA MARKET ANALYSIS BY TREATMENT TYPE
83. 6.83 ARGENTINA MARKET ANALYSIS BY TUMOR TYPE
84. 6.84 ARGENTINA MARKET ANALYSIS BY MARKET STAGE
85. 6.85 ARGENTINA MARKET ANALYSIS BY BIOMARKER STATUS
86. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT TYPE
87. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY TUMOR TYPE
88. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY MARKET STAGE
89. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY BIOMARKER STATUS
90. 6.90 MEA MARKET ANALYSIS
91. 6.91 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT TYPE
92. 6.92 GCC COUNTRIES MARKET ANALYSIS BY TUMOR TYPE
93. 6.93 GCC COUNTRIES MARKET ANALYSIS BY MARKET STAGE
94. 6.94 GCC COUNTRIES MARKET ANALYSIS BY BIOMARKER STATUS
95. 6.95 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT TYPE
96. 6.96 SOUTH AFRICA MARKET ANALYSIS BY TUMOR TYPE
97. 6.97 SOUTH AFRICA MARKET ANALYSIS BY MARKET STAGE
98. 6.98 SOUTH AFRICA MARKET ANALYSIS BY BIOMARKER STATUS
99. 6.99 REST OF MEA MARKET ANALYSIS BY TREATMENT TYPE
100. 6.100 REST OF MEA MARKET ANALYSIS BY TUMOR TYPE
101. 6.101 REST OF MEA MARKET ANALYSIS BY MARKET STAGE
102. 6.102 REST OF MEA MARKET ANALYSIS BY BIOMARKER STATUS
103. 6.103 KEY BUYING CRITERIA OF HEALTHCARE
104. 6.104 RESEARCH PROCESS OF MRFR
105. 6.105 DRO ANALYSIS OF HEALTHCARE
106. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
107. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
108. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
109. 6.109 HEALTHCARE, BY TREATMENT TYPE, 2024 (% SHARE)
110. 6.110 HEALTHCARE, BY TREATMENT TYPE, 2024 TO 2035 (USD Billion)
111. 6.111 HEALTHCARE, BY TUMOR TYPE, 2024 (% SHARE)
112. 6.112 HEALTHCARE, BY TUMOR TYPE, 2024 TO 2035 (USD Billion)
113. 6.113 HEALTHCARE, BY MARKET STAGE, 2024 (% SHARE)
114. 6.114 HEALTHCARE, BY MARKET STAGE, 2024 TO 2035 (USD Billion)
115. 6.115 HEALTHCARE, BY BIOMARKER STATUS, 2024 (% SHARE)
116. 6.116 HEALTHCARE, BY BIOMARKER STATUS, 2024 TO 2035 (USD Billion)
117. 6.117 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.2.2 BY TUMOR TYPE, 2025-2035 (USD Billion)
  3. 7.2.3 BY MARKET STAGE, 2025-2035 (USD Billion)
  4. 7.2.4 BY BIOMARKER STATUS, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.3.2 BY TUMOR TYPE, 2025-2035 (USD Billion)
  3. 7.3.3 BY MARKET STAGE, 2025-2035 (USD Billion)
  4. 7.3.4 BY BIOMARKER STATUS, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.4.2 BY TUMOR TYPE, 2025-2035 (USD Billion)
  3. 7.4.3 BY MARKET STAGE, 2025-2035 (USD Billion)
  4. 7.4.4 BY BIOMARKER STATUS, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.5.2 BY TUMOR TYPE, 2025-2035 (USD Billion)
  3. 7.5.3 BY MARKET STAGE, 2025-2035 (USD Billion)
  4. 7.5.4 BY BIOMARKER STATUS, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.6.2 BY TUMOR TYPE, 2025-2035 (USD Billion)
  3. 7.6.3 BY MARKET STAGE, 2025-2035 (USD Billion)
  4. 7.6.4 BY BIOMARKER STATUS, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.7.2 BY TUMOR TYPE, 2025-2035 (USD Billion)
  3. 7.7.3 BY MARKET STAGE, 2025-2035 (USD Billion)
  4. 7.7.4 BY BIOMARKER STATUS, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.8.2 BY TUMOR TYPE, 2025-2035 (USD Billion)
  3. 7.8.3 BY MARKET STAGE, 2025-2035 (USD Billion)
  4. 7.8.4 BY BIOMARKER STATUS, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.9.2 BY TUMOR TYPE, 2025-2035 (USD Billion)
  3. 7.9.3 BY MARKET STAGE, 2025-2035 (USD Billion)
  4. 7.9.4 BY BIOMARKER STATUS, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.10.2 BY TUMOR TYPE, 2025-2035 (USD Billion)
  3. 7.10.3 BY MARKET STAGE, 2025-2035 (USD Billion)
  4. 7.10.4 BY BIOMARKER STATUS, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.11.2 BY TUMOR TYPE, 2025-2035 (USD Billion)
  3. 7.11.3 BY MARKET STAGE, 2025-2035 (USD Billion)
  4. 7.11.4 BY BIOMARKER STATUS, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.12.2 BY TUMOR TYPE, 2025-2035 (USD Billion)
  3. 7.12.3 BY MARKET STAGE, 2025-2035 (USD Billion)
  4. 7.12.4 BY BIOMARKER STATUS, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.13.2 BY TUMOR TYPE, 2025-2035 (USD Billion)
  3. 7.13.3 BY MARKET STAGE, 2025-2035 (USD Billion)
  4. 7.13.4 BY BIOMARKER STATUS, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.14.2 BY TUMOR TYPE, 2025-2035 (USD Billion)
  3. 7.14.3 BY MARKET STAGE, 2025-2035 (USD Billion)
  4. 7.14.4 BY BIOMARKER STATUS, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.15.2 BY TUMOR TYPE, 2025-2035 (USD Billion)
  3. 7.15.3 BY MARKET STAGE, 2025-2035 (USD Billion)
  4. 7.15.4 BY BIOMARKER STATUS, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.16.2 BY TUMOR TYPE, 2025-2035 (USD Billion)
  3. 7.16.3 BY MARKET STAGE, 2025-2035 (USD Billion)
  4. 7.16.4 BY BIOMARKER STATUS, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.17.2 BY TUMOR TYPE, 2025-2035 (USD Billion)
  3. 7.17.3 BY MARKET STAGE, 2025-2035 (USD Billion)
  4. 7.17.4 BY BIOMARKER STATUS, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.18.2 BY TUMOR TYPE, 2025-2035 (USD Billion)
  3. 7.18.3 BY MARKET STAGE, 2025-2035 (USD Billion)
  4. 7.18.4 BY BIOMARKER STATUS, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.19.2 BY TUMOR TYPE, 2025-2035 (USD Billion)
  3. 7.19.3 BY MARKET STAGE, 2025-2035 (USD Billion)
  4. 7.19.4 BY BIOMARKER STATUS, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.20.2 BY TUMOR TYPE, 2025-2035 (USD Billion)
  3. 7.20.3 BY MARKET STAGE, 2025-2035 (USD Billion)
  4. 7.20.4 BY BIOMARKER STATUS, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.21.2 BY TUMOR TYPE, 2025-2035 (USD Billion)
  3. 7.21.3 BY MARKET STAGE, 2025-2035 (USD Billion)
  4. 7.21.4 BY BIOMARKER STATUS, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.22.2 BY TUMOR TYPE, 2025-2035 (USD Billion)
  3. 7.22.3 BY MARKET STAGE, 2025-2035 (USD Billion)
  4. 7.22.4 BY BIOMARKER STATUS, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.23.2 BY TUMOR TYPE, 2025-2035 (USD Billion)
  3. 7.23.3 BY MARKET STAGE, 2025-2035 (USD Billion)
  4. 7.23.4 BY BIOMARKER STATUS, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.24.2 BY TUMOR TYPE, 2025-2035 (USD Billion)
  3. 7.24.3 BY MARKET STAGE, 2025-2035 (USD Billion)
  4. 7.24.4 BY BIOMARKER STATUS, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.25.2 BY TUMOR TYPE, 2025-2035 (USD Billion)
  3. 7.25.3 BY MARKET STAGE, 2025-2035 (USD Billion)
  4. 7.25.4 BY BIOMARKER STATUS, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.26.2 BY TUMOR TYPE, 2025-2035 (USD Billion)
  3. 7.26.3 BY MARKET STAGE, 2025-2035 (USD Billion)
  4. 7.26.4 BY BIOMARKER STATUS, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.27.2 BY TUMOR TYPE, 2025-2035 (USD Billion)
  3. 7.27.3 BY MARKET STAGE, 2025-2035 (USD Billion)
  4. 7.27.4 BY BIOMARKER STATUS, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.28.2 BY TUMOR TYPE, 2025-2035 (USD Billion)
  3. 7.28.3 BY MARKET STAGE, 2025-2035 (USD Billion)
  4. 7.28.4 BY BIOMARKER STATUS, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.29.2 BY TUMOR TYPE, 2025-2035 (USD Billion)
  3. 7.29.3 BY MARKET STAGE, 2025-2035 (USD Billion)
  4. 7.29.4 BY BIOMARKER STATUS, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.30.2 BY TUMOR TYPE, 2025-2035 (USD Billion)
  3. 7.30.3 BY MARKET STAGE, 2025-2035 (USD Billion)
  4. 7.30.4 BY BIOMARKER STATUS, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Ntrk Fusion Gene Positive Advanced Solid Tumor Market Segmentation

Ntrk Fusion Gene Positive Advanced Solid Tumor Market By Treatment Type (USD Billion, 2025-2035)

Targeted Therapy
Chemotherapy
Immunotherapy
Surgery
Radiation Therapy

Ntrk Fusion Gene Positive Advanced Solid Tumor Market By Tumor Type (USD Billion, 2025-2035)

Lung Cancer
Colorectal Cancer
Breast Cancer
Pancreatic Cancer
Sarcoma

Ntrk Fusion Gene Positive Advanced Solid Tumor Market By Market Stage (USD Billion, 2025-2035)

Early Stage
Advanced Stage
Metastatic Stage

Ntrk Fusion Gene Positive Advanced Solid Tumor Market By Biomarker Status (USD Billion, 2025-2035)

NTRK1 Gene Fusion Positive
NTRK2 Gene Fusion Positive
NTRK3 Gene Fusion Positive

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035